Sanofi Exit From Sickle Cell Gene Therapy Leaves Sangamo With Difficult Decision

Adds To Hemophilia A Problems

 
• By Andrew McConaghie
  
Sangamo
Sanofi's decision means Sangamo has just pharma partner left - Pfizer - among its clinical trial programs. • Source: Alamy
Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from Business

More from Scrip